CY1111443T1 - Ιατρικη συνθεση για την αναστολη της εκφρασης της ατρ-κιτρικης λυασης και η χρηση της - Google Patents

Ιατρικη συνθεση για την αναστολη της εκφρασης της ατρ-κιτρικης λυασης και η χρηση της

Info

Publication number
CY1111443T1
CY1111443T1 CY20111100089T CY111100089T CY1111443T1 CY 1111443 T1 CY1111443 T1 CY 1111443T1 CY 20111100089 T CY20111100089 T CY 20111100089T CY 111100089 T CY111100089 T CY 111100089T CY 1111443 T1 CY1111443 T1 CY 1111443T1
Authority
CY
Cyprus
Prior art keywords
expression
atp
inhibit
citrate lyase
medical composition
Prior art date
Application number
CY20111100089T
Other languages
English (en)
Inventor
Yoshiro Kitahara
Tomohisa Okutsu
Akira Mitsui
Akira Okano
Original Assignee
Ajinomoto Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co., Inc. filed Critical Ajinomoto Co., Inc.
Publication of CY1111443T1 publication Critical patent/CY1111443T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση παρέχει φαρμακευτική σύνθεση για την καταστολή της έκφρασης της κιτρικής λυάσης ΑΤΡ, η οποία περιέχει μια ένωση που καταστέλλει την έκφραση της κιτρικής λυάσης ΑΤΡ με την χορήγηση in vivo. Οι ενώσεις καταστέλλουν την έκφραση της κιτρικής λυάσης ΑΤΡ με την in vivo χορήγηση περιλαμβάνουν παράγοντες έκκρισης ινσουλίνης όπως είναι η νατεγλινίδη. Αυτή η φαρμακευτική σύνθεση είναι αποτελεσματική στην πρόληψη, τη βελτίωση και την αντιμετώπιση του μεταβολικού συνδρόμου, συγκεκριμένα των ηπατικών διαταραχών σχετικών με τον ανώμαλο μεταβολισμό του λίπους όπως είναι το λιπαρό ήπαρ και η NASH.
CY20111100089T 2002-05-28 2011-01-27 Ιατρικη συνθεση για την αναστολη της εκφρασης της ατρ-κιτρικης λυασης και η χρηση της CY1111443T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002154397 2002-05-28
EP03733109A EP1547614B1 (en) 2002-05-28 2003-05-28 Medicinal composition for inhibiting the expression of atp-citrate lyase and use thereof

Publications (1)

Publication Number Publication Date
CY1111443T1 true CY1111443T1 (el) 2015-08-05

Family

ID=29561357

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100089T CY1111443T1 (el) 2002-05-28 2011-01-27 Ιατρικη συνθεση για την αναστολη της εκφρασης της ατρ-κιτρικης λυασης και η χρηση της

Country Status (12)

Country Link
EP (1) EP1547614B1 (el)
JP (1) JP4433496B2 (el)
KR (1) KR100983990B1 (el)
AT (1) ATE495740T1 (el)
AU (1) AU2003241823A1 (el)
CY (1) CY1111443T1 (el)
DE (1) DE60335810D1 (el)
DK (1) DK1547614T3 (el)
ES (1) ES2359910T3 (el)
PT (1) PT1547614E (el)
SI (1) SI1547614T1 (el)
WO (1) WO2003099332A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5063369B2 (ja) * 2006-02-08 2012-10-31 学校法人 久留米大学 メグリチニド類を含有する肝臓線維化予防用医薬組成物
US20120052054A1 (en) * 2009-04-13 2012-03-01 Shiseido Company, Ltd. Method for preventing skin elasticity loss by suppressing increase of subcutaneous fat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
GB9209628D0 (en) * 1992-05-05 1992-06-17 Smithkline Beecham Plc Compounds
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
CO5200844A1 (es) * 1999-09-17 2002-09-27 Novartis Ag Una combinacion que comprende nateglinida y cuando por menos otro compuesto antidiabetico usada para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con dibetes
EP1218015A2 (en) * 1999-10-08 2002-07-03 Novartis AG Pharmaceutical composition of nateglinide and another antidiabetic agent
EP1229026A4 (en) * 1999-11-10 2003-09-24 Takeda Chemical Industries Ltd ALKOXYIMINOALKANSÄURE DERIVATIVES
EP1283054A4 (en) * 2000-03-17 2006-04-12 Ajinomoto Kk MEDICAMENTS FOR TREATING THE COMPLICATIONS OF DIABETES AND NEUROPATHIES AND USE THEREOF

Also Published As

Publication number Publication date
KR20050008745A (ko) 2005-01-21
EP1547614A1 (en) 2005-06-29
DK1547614T3 (da) 2011-04-04
EP1547614A4 (en) 2007-09-05
JPWO2003099332A1 (ja) 2005-09-22
ES2359910T3 (es) 2011-05-30
ATE495740T1 (de) 2011-02-15
SI1547614T1 (sl) 2011-04-29
EP1547614B1 (en) 2011-01-19
AU2003241823A1 (en) 2003-12-12
WO2003099332A1 (fr) 2003-12-04
PT1547614E (pt) 2011-04-06
DE60335810D1 (de) 2011-03-03
KR100983990B1 (ko) 2010-09-30
JP4433496B2 (ja) 2010-03-17

Similar Documents

Publication Publication Date Title
MX2009002924A (es) Derivados de azetidinona espirociclica para el tratamiento de trastornos del metabolismo de los lipidos, el dolor, la diabetes y otros trastornos.
MA33720B1 (fr) Inhibiteurs peptiques cycliques de la replication du virus de l&#39;hépatite c
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BRPI0607536A2 (pt) tratamento de dor
BR112014004845A2 (pt) pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada
MX2009002921A (es) Derivados de azetidinona para el tratamiento de trastornos del metabolismo lipidico.
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
BRPI0510370A (pt) derivados de ácido fenoxi-alquil-carboxìlico no tratamento de doenças inflamatórias
AR044337A1 (es) Procedimiento para potenciar la cognicion usando ziprasidona
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
MX2009006768A (es) Metodos, compuestos, y composiciones para tratar trastornos metabolicos y diabetes.
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
EA200501105A1 (ru) Фармацевтическая композиция
IN2014DN08582A (el)
EA201390659A1 (ru) Способы лечения с применением липидных соединений
CY1112637T1 (el) Παραγων για την προληψη και αγωγη των παθησεων του ηπατος περιεχοντας παραγωγο πυραζολοπυριμιδινης
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
UA92498C2 (ru) Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
EA200901237A1 (ru) Применение димирацетама при лечении хронической боли
MA35363B1 (fr) Utilisation d&#39;un composé organisation dans le traitement du syndrome de noonan
CY1111443T1 (el) Ιατρικη συνθεση για την αναστολη της εκφρασης της ατρ-κιτρικης λυασης και η χρηση της
CO6612211A2 (es) Derivado de amida que tiene una acción hipoglucémica y/o una acción protectora de células b o pancreas
AR057570A1 (es) Derivados de n-sulfamoil-n&#39;-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o